BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36438482)

  • 1. The PROTAC selectively degrading Bcl-x
    Zhang S; Chen Y; Xu Z; Yang J; Sun R; Wang J; Sun Y; Jiang B; Yang X; Tan W
    Theranostics; 2022; 12(17):7476-7490. PubMed ID: 36438482
    [No Abstract]   [Full Text] [Related]  

  • 2. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists.
    Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABT-199 inhibits Hedgehog pathway by acting as a competitive inhibitor of oxysterol, rather as a BH3 mimetic.
    Wang J; Zhang Y; Huang WJ; Yang J; Tang WG; Huang TM; Tan WF
    Acta Pharmacol Sin; 2021 Jun; 42(6):1005-1013. PubMed ID: 32855528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenovirus vector-mediated Gli1 siRNA induces growth inhibition and apoptosis in human pancreatic cancer with Smo-dependent or Smo-independent Hh pathway activation in vitro and in vivo.
    Guo J; Gao J; Li Z; Gong Y; Man X; Jin J; Wu H
    Cancer Lett; 2013 Oct; 339(2):185-94. PubMed ID: 23791879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
    He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
    Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
    He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
    Gruber W; Hutzinger M; Elmer DP; Parigger T; Sternberg C; Cegielkowski L; Zaja M; Leban J; Michel S; Hamm S; Vitt D; Aberger F
    Oncotarget; 2016 Feb; 7(6):7134-48. PubMed ID: 26784250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
    You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-apoptotic protein BCL-XL as a therapeutic vulnerability in gastric cancer.
    Wei Y; Zhang L; Wang C; Li Z; Luo M; Xie G; Yang X; Li M; Ren S; Zhao D; Gao R; Gong JN
    Animal Model Exp Med; 2023 Jun; 6(3):245-254. PubMed ID: 37271936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Pancreatic Cancer Cell-Induced Paracrine Hedgehog Signaling by Liver X Receptor Agonists and Oxy16, a Naturally Occurring Oxysterol.
    Wang F; Stappenbeck F; Matsui W; Parhami F
    J Cell Biochem; 2017 Mar; 118(3):499-509. PubMed ID: 27490478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of IAP-recruiting BCL-X
    Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABT-737 suppresses aberrant Hedgehog pathway and overcomes resistance to smoothened antagonists by blocking Gli.
    Huang W; Liu H; Tan W; Wang J
    Med Oncol; 2022 Sep; 39(12):188. PubMed ID: 36071246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B13, a well-tolerated inhibitor of hedgehog pathway, exhibited potent anti-tumor effects against colorectal carcinoma in vitro and in vivo.
    Wu H; Zhang L; Chen B; Ou B; Xu J; Tian N; Yang D; Ai Y; Chen Q; Quan D; Zhang T; Lv L; Tian Y; Zhang J; Wu S
    Bioorg Chem; 2023 Jun; 135():106488. PubMed ID: 36989734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A selective BCL-X
    Khan S; Zhang X; Lv D; Zhang Q; He Y; Zhang P; Liu X; Thummuri D; Yuan Y; Wiegand JS; Pei J; Zhang W; Sharma A; McCurdy CR; Kuruvilla VM; Baran N; Ferrando AA; Kim YM; Rogojina A; Houghton PJ; Huang G; Hromas R; Konopleva M; Zheng G; Zhou D
    Nat Med; 2019 Dec; 25(12):1938-1947. PubMed ID: 31792461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive feedback of SuFu negating protein 1 on Hedgehog signaling promotes colorectal tumor growth.
    Yan Z; Cheng M; Hu G; Wang Y; Zeng S; Huang A; Xu L; Liu Y; Shi C; Deng L; Lu Q; Rao H; Lu H; Chen YG; Luo S
    Cell Death Dis; 2021 Feb; 12(2):199. PubMed ID: 33608498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
    Li QR; Zhao H; Zhang XS; Lang H; Yu K
    Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hedgehog Signaling and Truncated GLI1 in Cancer.
    Doheny D; Manore SG; Wong GL; Lo HW
    Cells; 2020 Sep; 9(9):. PubMed ID: 32957513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors.
    Benvenuto M; Masuelli L; De Smaele E; Fantini M; Mattera R; Cucchi D; Bonanno E; Di Stefano E; Frajese GV; Orlandi A; Screpanti I; Gulino A; Modesti A; Bei R
    Oncotarget; 2016 Feb; 7(8):9250-70. PubMed ID: 26843616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
    Jia Y; Han L; Ramage CL; Wang Z; Weng CC; Yang L; Colla S; Ma H; Zhang W; Andreeff M; Daver N; Jain N; Pemmaraju N; Bhalla K; Mustjoki S; Zhang P; Zheng G; Zhou D; Zhang Q; Konopleva M
    Haematologica; 2023 Oct; 108(10):2626-2638. PubMed ID: 37078252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
    Lv D; Pal P; Liu X; Jia Y; Thummuri D; Zhang P; Hu W; Pei J; Zhang Q; Zhou S; Khan S; Zhang X; Hua N; Yang Q; Arango S; Zhang W; Nayak D; Olsen SK; Weintraub ST; Hromas R; Konopleva M; Yuan Y; Zheng G; Zhou D
    Nat Commun; 2021 Nov; 12(1):6896. PubMed ID: 34824248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.